Bristol-Myers posts Q1 beat despite growth headwinds [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
The Princeton, New Jersey-based pharma giant reported $11.8B in revenue for the quarter with ~5% YoY growth as its multiple myeloma therapy Revlimid, facing generic competition, exceeded expectations, adding $1.7B to the topline. Revenue from Revlimid continued to drop with a ~5% YoY decline in Q1, even as its contribution to BMY's topline exceeded $1.2B projected by analysts, according to Bloomberg data. However, Opdivo, an anti-PD-1 immunotherapy rivaling Merck's ( MRK ) Keytruda, fell short of consensus, adding $2.0B with a ~6% YoY drop. Abecma, a CAR-T cell therapy that BMY markets with 2seventy bio ( NASDAQ: TSVT ), brought $82M, indicating a ~44% YoY decline. Meanwhile, Bristol-Myers' ( NYSE: BMY ) blood thinner Eliquis, marketed with Pfizer ( NYSE: PFE ), topped consensus, adding $3.7B to the topline with ~9% YoY growth. However, the company has swung to a loss in Q1 with a negative $5.89 earnings per share, driven by a one-time charge of $6.30 related to recently clos
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Here's Why Merck (MRK) is a Strong Momentum Stock [Yahoo! Finance]Yahoo! Finance
- Generic Sterile Injectable Market Size to Worth USD 108.54 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- 4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration [Yahoo! Finance]Yahoo! Finance
- Merck reports data from Phase III gastric cancer treatment trial [Yahoo! Finance]Yahoo! Finance
- The top pharmaceutical companies by R&D expenditure [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 5/3/24 - Form 10-Q
- 5/2/24 - Form 4
- 5/2/24 - Form 4
- MRK's page on the SEC website